Tailoring ARPIs according to CV morbidity in a patient with mHSPC on doublet therapy

12 Nov 2026
Prof. Matthew Chiu
Prof. Matthew ChiuClinical Assistant Professor; Department of Clinical Oncology; The University of Hong Kong
Prof. Matthew Chiu
Prof. Matthew Chiu Clinical Assistant Professor; Department of Clinical Oncology; The University of Hong Kong
Tailoring ARPIs according to CV morbidity in a patient with mHSPC on doublet therapy








References:

  1. J Clin Oncol 2018;36:1080-1087.
  2. Nubeqa Hong Kong Prescribing Information.
  3. ESMO Open 2024;9:103736.
  4. NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer, version 5.2026.
  5. J Clin Oncol 2023;41:3584-3590.
  6. Eur Urol 2024;86:340-342.
  7. Lancet Oncol 2019;20:686-700.
  8. Ong M, et al, ASCO 2025, abstract TPS5129.
  9. Grimm MO, et al, ESMO 2025, abstract LBA92.
  10. N Engl J Med 2022;386:1132-1142.
  11. J Clin Oncol 2024;42:4271-4281.
  12. Prostate Cancer Prostatic Dis 2025;28:298-308.
  13. EAU Guidelines 2026. ISBN 978-94-92671-32-5J.
  14. J Clin Oncol 2026;44:doi:10.1200/JCO.2026.44.7_suppl.137.
  15. Eur Urol 2016;70:438-444.
  16. Int J Urol 2025;32:1640-1649.
  17. Nat Rev Urol 2019;16:335-336.
  18. Eur Urol Oncol 2025;8:1321-1332.
This special report is supported by an education grant from the industry.